ReviewReumatologia2020
Pathophysiology of hyperuricemia and its clinical significance - a narrative review.
Review in Reumatologia, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 99 citations in OpenAlex.
- Article
- Exploratory Mediation-Informed Analysis and Dose-Response Analysis of Uric Acid Reduction and Kidney Outcomes in SGLT2 Inhibitor Therapy Compared to Allopurinol.Medical sciences (Basel, Switzerland) · 2026Article
- Exosome-Mediated Intercellular Communication in the Pathological Processes of Gouty Arthritis and Its Treatment.International journal of molecular sciences · 2026Review
- Allopurinol and Febuxostat Hypersensitivity in a Patient with Young Onset Gout: A Case Report.Acta medica Philippina · 2026Article
- Article
- Lipid-Derived Cardiometabolic Indices in Normouricemic and Hyperuricemic Adults: A Retrospective Cross-Sectional Association Study.Healthcare (Basel, Switzerland) · 2025Article
- The association between calcium-phosphorus product and hyperuricemia varied in BMI groups: a mediation analysis study.Clinical rheumatology · 2025Article
- Design, Synthesis, and Biological Evaluation of Triazole-Linked Lignan-Monoterpenoid-Based Hybrid Molecules as Xanthine Oxidase Inhibitors with Potent In Vivo Efficacy.ACS medicinal chemistry letters · 2025Article
- Investigation of Pharmacological Mechanisms and Active Ingredients ofInternational journal of molecular sciences · 2025Article
- Molecular basis of the urate transporter URAT1 inhibition by gout drugs.Nature communications · 2025Article
- Volatile organic compound exposure is associated with hyperuricemia in the general population: an analysis of 6878 adults from the NHANES.Metabolomics : Official journal of the Metabolomic Society · 2025Article
- Anti-Hyperuricemic and Nephroprotective Effects of Hydrolysate Derived from Silkworm Pupae (Nutrients · 2025Article
- Associations of low-carbohydrate diets patterns with the risk of hyperuricemia: a national representative cross-sectional study in Korea.Nutrition journal · 2025Article
- A Review on Optical Biosensors for Monitoring of Uric Acid and Blood Glucose Using Portable POCT Devices: Status, Challenges, and Future Horizons.Biosensors · 2025Review
- Therapeutic effect of fecal microbiota transplantation on hyperuricemia mice by improving gut microbiota.Frontiers in microbiology · 2025Article
- Association of obesity with hyperuricaemia among HIV-positive patients on antiretroviral therapy in South-Western Uganda.African journal of laboratory medicine · 2025Article
- Chromene flavanones fromFrontiers in pharmacology · 2025Article
- The Therapeutic Management of Chemical and Herbal Medications on Uric Acid Levels and Gout: Modern and Traditional Wisdom.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Association between Body Mass Index and Serum Uric Acid: mediation analysis involving liver enzymes indicators.BMC public health · 2024Article
- Molecular basis of the urate transporter URAT1 inhibition by gout drugs.bioRxiv : the preprint server for biology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hyperuricemia, i.e. increased serum uric acid (UA) concentration, is a common problem in clinical practice. While there are clear guidelines concerning management of symptomatic hyperuricemia in acute conditions such as gout, urolithiasis or acute urate nephropathy, less is known about their secondary prevention. Moreover, despite the ongoing debate on the role of UA in the pathogenesis of chronic kidney disease, hypertension, cardiovascular disease and heart failure, the management of asymptomatic hyperuricemia in patients with these chronic conditions is still mainly up to physicians' judgement. Individual considerations should always be taken into account when prescribing urate-lowering therapy. In this narrative review study, we attempt to present current trends concerning treatment of patients with either symptomatic or asymptomatic hyperuricemia in the light of the available knowledge on the role of hyperuricemia in the development of gout, renal, cardiovascular and other diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.